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Different rates of disease progression may be associated with different human immunodeficiency virus type 1 (HIV-1)
promoter and/or transactivator activities. We therefore analyzed the sequences and activities of the first exon of Tat, tat1,
and the promoter/trans-acting responsive (TAR) regions amplified directly from peripheral blood mononuclear cells obtained
from five long-term nonprogressors and eight progressing HIV-1-infected individuals. The majority of tat1 alleles and
promoter/TAR regions from all patients were intact and showed comparable activities in transient reporter assays. A
substantial number of point mutations and some length variations were observed in the promoter/TAR region. In a single
nonprogressor, the Sp1 binding site 3 was consistently altered and the transcriptional activity in the presence of Tat was
diminished. Some LTR clones from a rapid progressor contained a fourth Sp1 binding site, which was associated with an
elevated basal promoter activity. These data suggest that defects in the promoter/TAR region or tat1 are rare and that
different promoter/transactivator activities are not commonly associated with different progression rates. q 1997 Academic
Press
INTRODUCTION 1994). Rhesus macaques experimentally infected with
nef-defective simian immunodeficiency virus have low
Disease progression in human immunodeficiency vi-
viral loads and develop no signs of immunodeficiency
rus type 1 (HIV-1) infection depends on the level of viral
(Kestler et al., 1991). These results strongly suggest that
replication in vivo (Coffin, 1995; Mellors et al., 1996). In
the viral phenotype can influence the clinical course ofprogressing individuals, replication of HIV-1 is continu-
HIV-1 infection.ous and highly productive, driving rapid turnover of CD4/
Efficient replication of HIV-1, which is a prerequisiteT-lymphocytes, eventually leading to the development of
for progressing infection, depends upon interactions ofAIDS (Wei et al., 1995; Ho et al., 1995). In subjects who
the viral trans-activator Tat with the trans-acting respon-remain asymptomatic, viral load is usually low and viral
sive region (TAR) in the long terminal repeats (LTRs)replication is less efficient (Pantaleo et al., 1995; Cao
(Fisher et al., 1986; Feng and Holland, 1988; Berkhout etet al., 1995). A multitude of viral and host factors may
al., 1989; Dingwall et al., 1989). HIV-1 gene expressioncontribute to the different levels of viral replication and
is also modulated by several highly conserved cis-actingthe different progression rates. Host factors may include
regulatory elements in the LTRs, including the TATA boxvariable susceptibility to infection and the ability to mount
and binding sites for the transcription factors NF-kB andan adequate immune response (Williams et al., 1991;
Sp1 (Garcia et al., 1989; Gaynor, 1992; Harrich et al.,Lifson et al., 1991; Greenough et al., 1994). Some long-
1989; Jones et al., 1986; Nabel and Baltimore, 1987). Interm asymptomatic individuals are infected with attenu-
contrast, most of the upstream U3 sequences in the viralated forms of HIV-1 containing deletions in the nef gene
LTR are less important for efficient viral replication(Kirchhoff et al., 1995; Deacon et al., 1995). Inactivating
(Gaynor, 1992) and are selectively deleted in vivo in themutations have also been identified in HIV-1 vif, vpr, vpu,
absence of an intact nef gene (Kirchhoff et al., 1994,tat1, and rev genes (Iversen et al., 1995; Michael et al.,
1995). These upstream LTR sequences seem to be of1995; Sabino et al., 1993). HIV-1 variants with increased
little relevance for transcription and replication in vivoreplicative capacity develop before disease progression
and may serve mainly as a Nef-coding region (Ilyinskii(Connor and Ho, 1994), and AIDS develops faster in in-
et al., 1994). Most data on HIV-1 Tat and LTR activityfants born to rapidly progressing mothers (Tovo et al.,
were derived from laboratory-adapted molecular clones
(Gaynor, 1992). A limited number of studies on naturally1 To whom correspondence and reprint requests should be
occurring tat1 and promoter/TAR variants have shownaddressed. Fax: 0049-9131-852101. E-mail: fkkirchh@viro.med.
uni-erlangen.de. that the basal and Tat-induced transcriptional activities
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vary considerably in different patients (Michael et al., TGG TGG TTG CTT CTT TCC 3*). Thereafter, 35 additional
cycles were performed with 100 pmol of each primer. The1994; Estable et al., 1996; Delassus et al., 1992). Longitu-
dinal study of a single patient over a 4-year period did not first primer pair amplified a 1.4-kb fragment spanning the
entire central part of the HIV-1 genome (vif, vpr, vpu, rev1,give indications for genotypes that were transcriptionally
more active during progression from asymptomatic to tat1). The first coding exon of Tat (tat1) was amplified with
100 pmol of primers pTAT5Eco (5* CGC GAA TTC GTCsymptomatic infection (Delassus et al., 1992). Koken et
al. (1992) identified a variant with a fourth Sp1 site in 1 of RAC ATA GCA GAA TAG 3*; R  [A,G]) and pTAT3Not (5*
CAG GGC GGC CGC GGT CCA CAC AAC TAT 3*). Restric-17 HIV-1-infected individuals. This variant had a slightly
higher promoter activity and outgrew viruses containing tion sites are underlined. DNA fragments were cut with
EcoRI and NotI, and tat1 alleles were cloned into an expres-three Sp1 sites. Thus far, it is not known to what extent
different transcriptional activities influence the different sion plasmid containing a CMV promoter (pcDNAIII; In-
vitrogen, San Diego, CA).rates of disease progression in HIV-1 infection.
We have analyzed the status and the activities of tat1 Amplification of LTR sequences was carried out with
the outer primer set pLTR5ex (5* GCT TGT TAC ACC CTAgenes and promoter/TAR regions derived directly from
the peripheral blood mononuclear cells (PBMC) from five TGA GCC TGC ATG 3*) and pLTR3ex (5* TCT GAG GGA
TCT CTA GTT ACC AGA GT 3*) and the inner primer pairlong-term nonprogressors and eight individuals with pro-
gressing HIV-1 infection. Consistent defects in tat1 or the pLTR5Sal (5* CCG CGT CGA CTT TCA TCA CGT GGC
CCG A3*) and pLTR3SstI (5* TCA GCG AGC TCA AGGpromoter/TAR region were not found in individuals with
long-term nonprogressing infection. Moreover, most tat1 CAA GCT TTA TTG AG 3*). PCR products were cut with
SalI and SstI and cloned upstream of the Luciferase re-alleles and promoter/TAR regions from the different
groups of patients showed comparable activities. How- porter gene.
As positive controls the LTR promoter/TAR region andever, we identified some sequence variations in the Sp1
binding sites, suggesting that more attenuated or more the first coding exon of tat were amplified from the HIV-1
NL4-3 clone (Adachi et al., 1986) and cloned as describedactive naturally occurring LTR variants may be present
in some individuals exhibiting different rates of progres- above. DNA sequences from multiple clones were deter-
mined with fluorescent-labeled nucleotides with a Modelsion.
373 automated DNA sequencer (Applied Biosystems). Nu-
cleotide sequences were analyzed with Version 7 of theMATERIALS AND METHODS
Genetics Computer Group, Inc. (GCG) software package.
Study subjects and sample preparation
Transactivation assaysBlood samples were obtained from patients followed
by the New England Area Comprehensive Hemophilia To assess the activity of various promoter/TAR regions
Center at the Medical Center of Central Massachusetts, and tat1 genes COS-7 cells were seeded at a 10-fold
Memorial Hospital, Worcester. Five nonprogressing (AD, dilution and transfected by the DEAE–dextran method
CO, DJ, HP, PC), four slowly progressing (BT, CW, CH, on the following day (Cullen, 1987). Cells were harvested
EP), and four progressing (BJ, FA, HE, MR) HIV-1-infected 48 to 72 hr posttransfection, washed twice with phos-
individuals were investigated. The data on CD4/ lympho- phate-buffered saline, resuspended in 50 ml extraction
cyte counts and HIV-1 RNA copy numbers are summa- buffer (100 mM KHPO4 , pH 7.8; 1 mM DTT), and subjected
rized in Table 1. The criteria for nonprogressing, slowly to four successive freeze–thaw cycles. Cell debris were
progressing, and progressing infection have been de- removed by centrifugation and 5 ml of the supernatants
scribed (Kirchhoff et al., 1995). PBMC were isolated by was used to determine the total protein concentration
centrifugation through Ficoll–Histopaque density gradi- with a commercial reagent (Bio-Rad). Luciferase assays
ents and genomic DNA was extracted from frozen PBMC were performed with the Promega assay system as rec-
samples by standard methods. Most blood samples were ommended by the manufacturer. To allow a better com-
obtained in 1993 or 1994. From two (tat1 genes), respec- parison among individual experiments, stock DNA prepa-
tively, three (promoter/TAR region) of the asymptomatic rations from NL4-3 tat1 and LTR control plasmids were
individuals’ blood samples from several independent always included as positive controls. The amount of Lu-
time points were analyzed. ciferase activity obtained after cotransfection of 1 mg of
each control plasmid was considered 100% activity, and
DNA analysis the activities of patient-derived tat1 alleles and promoter/
TAR regions were determined relative to this value.
PCR amplification of tat1 sequences was performed with
a nested PCR approach. First, 0.5 mg (progressing patients) Nucleotide sequence accession numbers
or 2.5 mg (nonprogressors) of genomic DNA was subjected
to 10 cycles of amplification with 5 pmol of primers pF15 The nucleotide sequence data reported in this paper
have been submitted to the GenBank nucleotide se-(5* GGA AAG GTG AAG GGG CAG 3*) and pF16 (5* GAG
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TABLE 1 the individual clone obtained from that PCR. The majority
of tat1 genes predict intact amino acid sequences (Fig.Summary Data of CD4 Counts and HIV-1 RNA Levels
1). Only one clone from a nonprogressor, HP91-B2, con-
Patient CD4/ Viral RNA copies/ml of plasmab tained a premature stop signal. No frame shift mutations
sample T-cellsa (years of sampling) were observed in any of the 85 clones obtained from the
13 patients analyzed (Fig. 1). Moreover, regions known
AD92 1339 BQL–732 (1993–1994)
to be important for a functional Tat, e.g., the seven CysAD93 1467
residues and the basic domain, were highly conservedCO83 1099 BQL–4568 (1991–1994)
CO86 1181 (Fig. 1). However, considerable variability was observed
CO89 637 between sequences obtained from different patients,
DJ93 711 BQL–338 (1993–1995) particularly in the C-terminal part of Tat (Fig. 1). In three
HP83 1927 BQL–294 (1993–1996)
samples obtained from nonprogressors (HP83, CO83,HP89 948
and PC93), and from one progressing patient, CW94, allHP91 1246
HP93 1156 tat1 genes analyzed predicted the same patient-specific
PC93 1416 677–1142 (1994–1995) amino acid sequences (Fig. 1). The proviral copy num-
BT94 444 9259 (1992) bers are extremely low in CO and HP (Kirchhoff et al.,
CW94 518 2426 (1993)
1995; Mariani et al., 1996; and data not shown). There-CH94 662 822–4677 (1993)
fore, sequence identity of different PCR clones derivedEP94 168 21232 (1993)
BJ93 61 n.d. from these individuals likely reflects the amplification of
FA94 19 38024 (1992) single proviral templates.
HE93 25 2458 (1993) Most of the 85 tat1 alleles analyzed appeared to en-
MR94 67 70111 (1993)
code functional Tat. However, on average, the Tat se-
quences contained 5.3 amino acid substitutions com-a Absolute number of CD4/ cells per mm3 in year of sampling for
genomic DNA preparation. pared to the consensus Tat sequence (nonprogressors,
b Quantitation of cell-free HIV-1 RNA genome copy numbers was 2.6; slow progressors, 7.4; and progressors, 9.7). It is
performed with the Roche Amplicor Assay kit. BQL, below quantitation difficult to predict the influence of these sequence varia-
limits. Threshold of detection, 200 copies/ml. n.d., not determined.
tions on Tat activity solely from the sequence data. There-
fore, all 85 tat1 exons were cloned downstream of the
CMV promoter in the pcDNA3 expression vector. Forquence database and have been assigned the accession
numbers AF000522 to AF000544. each of the 13 patients the activity of a representative
tat1 gene was examined in transient cotransfection
assays (Fig. 2). tat1 alleles selected for functional studiesRESULTS
from 9 of the 13 individuals were identical to the consen-
Sequences and functional activities of tat1 alleles
sus sequence for the respective patient. For the other 4
individuals (BT, EP, BJ, and FA) the tat1 allele mostThe first coding exon of Tat, tat1, was amplified from
DNA samples derived from uncultured PBMC obtained closely related to the patient-specific consensus was se-
lected (Fig. 1). A constant amount of the control LTRfrom five nonprogressing, four slowly progressing, and
four progressing HIV-1-infected individuals (Table 1). No construct (pALuc–NL4–3LTR) was cotransfected with
the Tat expression plasmids into COS-7 cells. Promotervariations in the electrophoretic mobility of the tat1 PCR
products were observed (data not shown). Our nested activities were assessed by Luciferase assay 48 to 72
hr later. tat1 alleles derived from the 13 individuals werePCR always yielded amplification products of the ex-
pected size for samples obtained from all progressing always tested in parallel with the same stock solutions
of the NL4-3 control plasmids. All 16 tat1 exons analyzedpatients and the nonprogressing patients AD, DJ, and
PC (data not shown). However, in agreement with our were found to be functionally active and transactivated
the NL4-3 promoter by a factor of 150- to 440-fold (Fig.previous data on nef gene analysis of the same patients
(Kirchhoff et al., 1995; Mariani et al., 1996), multiple reac- 2). Only up to 3-fold differences in the Tat-induced tran-
scriptional activities were observed (Fig. 2). The HP91-tions were necessary to obtain PCR products from pa-
tients HP and CO (CO83 2/4, CO86 2/4, CO93 0/4, HP83 A1 tat1 clone, which showed only 38% of the activity of
the NL4-3 tat1 clone in this assay, carried an unusual 351/2, HP91 2/6, and HP93 2/6; 83, 86, 91, and 93 refer to
the year that PBMC were obtained; other numbers give Q to H mutation. This amino acid substitution was absent
in the HP93-A1 tat1 allele, which was fully active (Figs.positive reactions per total numbers of PCRs performed).
The sequences of the cloned PCR fragments are shown 1 and 2). One of the seven HP91 tat1 clones obtained
from two independent PCR analyses did not contain thein Fig. 1. The first two letters of each identifier in Fig. 1
refer to the patient analyzed, the following two numbers 35 Q to H mutation, but was inactive due to a premature
termination codon (Fig. 1). Overall, the average transacti-give the year of PBMC isolation, the next letter gives the
individual PCR analysis, and the last number refers to vation values (nonprogressors 305 { 55; slow prog-
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FIG. 1. Alignment of the deduced amino acid sequences of the first Tat coding exon obtained from nonprogressing (top), slowly progressing
(middle), and progressing (bottom) HIV-1-infected individuals. Dashes indicate identity with the consensus sequence; stars indicate stop signals.
Variations are shown by the single amino acid code. Arrows indicate the clones tested in Luciferase assays. Acidic amino acids in the N-terminal
part are shown in boldface letters; the cysteine residues are shaded and the basic domain is boxed.
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FIG. 2. Activation of the Luciferase gene under control of the HIV-1 NL4-3 promoter by natural tat1 genes obtained from patients with different
rates of disease progression. As described under Materials and Methods, COS-7 cells were cotransfected with 1 mg DNA each of the pALuc–
NL4 –3 LTR plasmid and the expression plasmids carrying the tat1 genes indicated. Shown are average values from at least three experiments
performed in duplicate with different DNA preparations. The standard errors are indicated by the bars; numbers in the figure give the average
activation rates observed, and the broken line indicates 50% of NL4-3 tat1 activity. *CO86-1 and HP91-A1 were not included in the calculation of
the average transactivation levels.
ressors 349 { 59; and progressors 298 { 86) and the in a loss of some of the binding sites for the PCR primers.
Therefore, LTR sequences were obtained only from theabsolute activities (80 to 87% compared to the NL4-3
relatively early 83 and 89 time points (Fig. 3).tat1) obtained for 13 representative tat1 alleles from the
A total of 79 LTR clones were sequenced and aligned;5 nonprogressing, 4 slow progressing, and 4 progressing
43 sequences were derived from the nonprogressors, 17individuals were highly similar (Fig. 2).
from slow progressors, and 19 from rapid progressors.
Gross defects such as large deletions, insertions, or rear-Sequences and transcriptional activities of promoter/
rangements were not observed (Fig. 3). The average num-TAR regions
bers of point mutations per clone compared to the consen-
LTR core enhancer/TAR sequences were obtained from sus sequence were 4.0 for the nonprogressor group, 6.2
all 13 patients. For three of the nonprogressors (AD, CO, for the slow progressing group, and 8.3 for the progressing
and HP), sequences from multiple time points were ana- group. The frequency of G to A transitions was significantly
lyzed (Fig. 3). In contrast to the tat1 amplification, some higher in the nonprogressors (46%) compared to the other
length variations were observed (Fig. 3, and data not two groups (slow progressors, 11% and progressors, 21%;
shown). In patient CO, deletions in the U3 region of the P value  0.01%; x2 test; Yates-corrected).
The two NF-kB-binding sites were present in all clonesLTR accumulated over time (Kirchhoff et al., 1995), resulting
FIG. 3. Alignment of the 79 LTR promoter/TAR sequences obtained from the 13 patients analyzed in this study. Sequences are aligned with the
calculated consensus sequence. Refer to Fig. 1 for abbreviations. Dots indicate gaps introduced to optimize the alignment. The NF-kB binding
motifs, the Sp1 sites, and the TATAA sequence are underlined and shaded. The positions of the motifs for Ets, RBF-1, LEF, the E boxes, the MFNLP
region (most frequently naturally occurring length variation), the start of transcription, the TAR core region, and the TAR bulge and loop sequences
are also indicated. Arrows indicate clones tested in functional assays.
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FIG. 4. Activity of HIV-1 promoters from patients with different rates of disease progression with (/) or without (0) the addition of Tat expression
plasmid. COS-7 cells were transfected with the indicated LTR-Luciferase plasmids alone or cotransfected with an NL4-3 Tat expression plasmid.
For better comparison between independent experiments, stock DNA preparations from the NL4-3 LTR Luciferase and the NL4-3 Tat expression
plasmid were always included in duplicate as positive controls (100% activity). Thus, promoter activities relative to the NL4-3 promoter together
with values for standard errors are shown. Numbers at the bottom of the figure indicate the ratio of Luciferase activities observed in the presence
or absence of Tat; the broken line indicates 50% of the NL4-3 control constructs. Average values obtained from at least three independent experiments
are shown. *The values obtained for the BJ-93A2 LTR were not included in the calculation of the average.
and generally well conserved. Only independent clones PCR amplifications from one nonprogressor, PC, con-
tained multiple changes in the Sp1-3 site, GAGGCGT-obtained from the CO83 sample contained G-to-A muta-
tions at position 3 of the NF-kB1 and position 2 of the GGC to GAGGTGGAGA. LTR clones from this patient
showed consistently about three- to fivefold diminishedNF-kB2 binding sites (Fig. 3). Nonetheless, these CO83
LTR clones showed 36 { 4% of the control LTR activity activated transcriptional activity (Figs. 4 and 6, and data
not shown).in the presence of Tat (data not shown).
The three Sp1 sites were less well conserved than the Some duplications of 4 (PC), 6 (CW), and 20 (BT) nucle-
otides just upstream of the NF-kB binding sites wereNF-kB-binding sites. Most variations were observed in
Sp1-2 and Sp1-3 (Fig. 3). The DJ93-A2 LTR clone con- observed in sequences derived from 3 of the 13 individu-
als (Fig. 3). This length variable region has recently beentained several G-to-A transitions in two Sp1 binding sites
and showed 26 { 4% of NL4-3 promoter activity after named ‘‘most frequent naturally occurring length varia-
tion’’ (MFNLP) (Estable et al., 1996). The same authorstransactivation (data not shown). Four of 10 LTR clones
obtained from four independent PCR amplifications from describe high conservation of an 5*-ACYGCTGA-3* motif.
All 5 LTR clones obtained from the progressing patienta rapid progressor, BJ, contained a 12-bp duplication
which creates a fourth Sp1 site (Fig. 3, and data not BJ contained a single point mutation in this motif, ACYGA-
TGA (Fig. 3), but showed full transcriptional activity (Figs.shown). The electrophoretic mobility of the PCR frag-
ments obtained from this patient also suggests that about 4–6). In our experiments length variations in the MFNLP
region were not associated with significant higher orhalf of the proviral sequences contain this duplication
(data not shown). Clones carrying the additional Sp1 lower promoter activities in the presence or absence of
Tat (Fig. 4). Some crucial elements in the LTR, e.g., thebinding site showed a normal level of activation in the
presence of Tat, but elevated basal transcriptional activ- TATAA box and the TAR region, were highly conserved.
Some variations in the trinucleotide bulge, TCT to TCA,ity (Fig. 4). In contrast, all 10 clones obtained from four
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were observed in all 10 clones from the two fast prog- above, LTR sequences obtained from the same patient
showed diminished activity (Fig. 2). In contrast, in oneressors, FA and MR. These LTR clones showed normal
response to Tat (Fig. 4). Also some tolerable changes in slowly progressing (BT) and two of the three progressing
patients (BJ and HE) tested, about 2-fold higher Lucifer-the hexanucleotide loop sequence CTGGGA to CCGGGA
were observed in a total of 5 clones from individuals EP, ase activities were observed at the 50- and 250-ng dose
levels (Figs. 5B and 5C). To test if the diminished activi-FA, and HE. In contrast two G-to-A transitions in the
PC93-A2 TAR loop sequence resulted in about 50-fold ties of PC promoter/TAR regions were representative,
additional clones from PC were tested. The PC93-A1reduced activity in the presence of Tat (Fig. 6; and data
not shown). Compared to the consensus promoter/TAR clone was inactive because of a two-point mutation in
the TAR bulge sequence (Figs. 3 and 6). Only marginalsequence all 5 LTR clones from patient FA contained a
C r T mutation at position /10 and a second mutation differences in activity among different PC clones and
controls were observed at the 50-ng dose. However, theG r A at position /50 (Fig. 4). This second mutation
would restore the base pairing in the secondary structure PC promoter/TAR sequences showed only slightly in-
creased levels of activity at higher Tat concentrationsof the TAR RNA. Similar changes were observed in the
EP94-A2 LTR clone (Fig. 4). (Fig. 6). The average activities at the 250-ng and 1-mg
doses were 33{ 5 and 38{ 4%, respectively, of the NL4-The average Tat-induced transcriptional activities of
the promoter/TAR regions derived from the five nonpro- 3 control plasmids. Slightly higher values were obtained
when the NL4-3 tat1 was used, but the maximal activitiesgressing, three slowly progressing, and four progressing
individuals were highly similar (80 to 87% compared to observed with all PC LTR alleles were still about 2-fold
diminished (Fig. 6). These results indicate that in ourthe NL4-3 control construct) (Fig. 4). The promoter/TAR
regions derived from the three different groups of HIV-1- experimental system, both tat1 and LTR sequences from
PC contribute to the lower activities. However, the majorinfected individuals were transactivated about 450-fold
in the presence of NL4-3 Tat (Fig. 4). Also the average factor is apparently that the PC promoter/TAR region is
saturated at a relatively low concentration of Tat (Figs.levels of basal transcriptional activity did not differ signifi-
cantly among the different groups of infected individuals 5A and 6). In agreement with our previous data, different
alleles from patient BJ showed about 2-fold higher Lucif-(Fig. 4).
erase activities at the 50- and 250-ng dose levels (Figs.
5C and 6). At high concentrations of Tat the averageCombined activities of patient-specific tat1 genes and
Luciferase activities were about 2-fold elevated in thepromoter/TAR regions
progressing group compared to the nonprogressing
group when both tat1 and the promoter/TAR sequencesNext, representative tat1 alleles and LTR sequences
derived from the same patient were tested. To compare were derived from the same patient (Fig. 5D). However,
this mainly reflects the low activities of the PC alleles.the promoter/TAR activities at limited amounts of Tat, a
constant amount of each LTR plasmid (1 mg) was added Overall, the results show that most tat1 alleles and pro-
moter/TAR regions from four of the five nonprogressingto 0, 10, 50, 250, and 1000 ng of the Tat-expression plas-
mids and transfected into COS-7 cells. As shown in Fig. individuals are fully active in this transient assay.
5 the promoter/TAR sequences from all patients were
activated in a dose-dependent manner. In most cases DISCUSSION
increasing the amount of Tat expression plasmid by a
factor of 100 (10 to 1000 ng) resulted in an approximately We have analyzed the tat1 and promoter/TAR se-
quences and activities from a group of 13 well-character-10-fold elevated level of Luciferase activity (Fig. 5). Repre-
sentative promoter/TAR elements derived from some in- ized HIV-1-infected hemophiliacs with different rates of
disease progression. It has previously been suggesteddividuals (AD, HP, PC, BT, EP, BJ, and HE) seemed to be
fully activated by cotransfection of 250 ng Tat vector DNA, that defective tat1 genes may limit the spread of HIV-1
in vivo, and a single individual with a high frequency ofwhereas others (NL4-3, CO, and FA) showed about 1.6-
to 2-fold higher activities when 1 mg Tat expression plas- about 50% tat-defective proviruses has been described
(Sabino et al., 1993). Others found defective tat1 genesmid was cotransfected. Cotransfection of tat1 alleles and
promoter/TAR regions obtained from most nonprogress- with a frequency of 10 to 15% in sequential samples
taken over a 4-year period from a progressing HIV-1-ing (AD, CO, DJ, and HP) and slowly progressing (CH,
EP) patients and from one fast progressing (HE) patient infected individual (Meyerhans et al., 1989). No selection
for more active tat1 alleles during disease progressionresulted in Luciferase activities similar to or slightly be-
low those obtained for the NL4-3 tat1 and LTR sequences was found in this individual (Delassus et al., 1992). In
our study all 40 tat1 genes from progressing, and 47 of(Fig. 5). In contrast, the activities obtained with se-
quences from one nonprogressor (PC) were consistently 48 tat1 alleles amplified from nonprogressing individuals,
predicted intact reading frames. Moreover, at least in our3- to 5-fold diminished after cotransfection of 250 ng or
1 mg of Tat expression plasmid (Fig. 5A). As mentioned transient assay, no significant differences in the levels of
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FIG. 5. Dose-dependent transactivation of natural HIV-1 promoters from (A) nonprogressing, (B) slowly progressing, and (C) progressing individuals.
Average values obtained for each group are shown in (D). Representative LTR clones obtained from each patient were cotransfected with increasing
amounts of vector expressing the predominant form of Tat detected in this patient (sequences used are shown in Figs. 1 and 3).
transactivation of the control NL4-3 promoter/TAR region Similar to previous studies (Estable et al., 1996; Koken
et al., 1992; Michael et al., 1994) we found high conserva-with representative tat1 alleles from the different groups
of patients were observed. Our results suggest that tat- tion of the TATA box, the three Sp1, and the two NF-kB
sites and some length variations in the Sp1 sites and indefective proviruses in PBMC are rare and that different
tat1 gene activities are not commonly associated with the MFNLP region just upstream of the NF-kB2 binding
site. Estable et al. (1996) described insertions of 15 todifferent rates of disease progression in the majority of
HIV-1-infected individuals. 34 bp that duplicated 5*-ACYGCTGA-3* motifs in 16 of
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tions in the MFNLP region or an intact ACYGCTGA motif
has any functional relevance.
In recent studies duplications of Sp1 sites were found
in 2 of 42 (Estable et al., 1996), 1 of 17 (Koken et al.,
1992), and 1 of 4 HIV-1-infected individuals (Michael et
al., 1994). We found duplication of a single Sp1 site in
about half of the clones derived from a progressing indi-
vidual presented in this study, but not in any of 208 LTR
sequences derived from 38 individuals we analyzed more
recently (data not shown). Accordingly, duplications in
Sp1 sites are rare and occur in only about 4% of the
HIV-1-infected individuals. Thus far, reported LTRs with
additional Sp1 sites were derived from progressing indi-
viduals. In agreement with our results slightly elevated
basal activities of the variants with four Sp1 sites have
been described (Michael et al., 1994; Koken et al., 1992).
Moreover, a variant with a fourth Sp1 site outgrew wild-
type virus when the two forms were cocultivated (Koken
et al., 1992). Nonetheless, too little data on naturally oc-
curing duplications of Sp1 sites have been published to
allow the conclusion that these duplications are associ-
ated with a more rapid disease progression.
Five long-term nonprogressors were analyzed in this
study. In one individual, CO, infection with an attenuated,
nef-defective form of HIV-1 is very likely responsible for
FIG. 6. Dose-dependent transactivation of different PC promoter/ the nonprogressive status (Kirchhoff et al., 1995). A sec-
TAR alleles by the PC (*) or NL4-3 (#) tat1 genes. For comparison,
ond nonprogressor, HP, also showed a high frequencytransactivation levels obtained with the control NL4-3 constructs and
of defective nef genes, although intact, functional activetwo BJ promoter/TAR alleles are shown.
forms could also be detected (Mariani et al., 1996). The
majority of tat1 alleles and promoter/TAR regions from
these two and two additional nonprogressors, AD and42 HIV-1-infected individuals. They suggested that such
duplications occur in LTRs in which the same motif was DJ, showed activities comparable to the NL4-3 control
constructs. In one nonprogressor, PC, the Sp1-3 site wasdisrupted. We found short insertions of 4, 6, and 20 bp
in the LTR MFNLP region in sequences derived from 3 of altered and the transcriptional activity in the presence of
Tat about three- to fivefold diminished. Although somethe 13 individuals analyzed. The 4- and 20-bp insertions
reconstituted the 5*-ACYGCTGA-3* motif. The sequence sequence variations in the Sp1-3 site are not uncommon,
they are usually restricted to positions 5, 9, and 10 (GAG-generated by the 6-bp insertion contained an imperfect
5*-ACYGATGA-3* motif. In one progressor the same point GCGTGGC). The alterations at positions 7 and 8 (GAG-
GCGTGGC to GAGGTGGAGA) observed in all LTR clonesmutation was present, and no duplications were ob-
served. More recently, we analyzed LTR sequences from from PC are uncommon. Comparable changes were not
observed in LTR sequences derived from a total of 11338 individuals at different stages of infection (data not
shown). Small duplications or insertions of 9 to 28 bp in individuals analyzed by our group or described by others
(Estable et al., 1996; Michael et al., 1994; Koken et al.,the MFNLP region were present in sequences from 5 of
the 38 HIV-1-infected individuals. Overall we observed 1992; and data not shown). Since no other sequence
abnormalities were present in the PC promoter/TAR re-length variations in the MFNLP region derived from 8 of
51 individuals (16%), which is somewhat lower than the gions these alterations are likely to be the cause for the
diminished transcriptional activities. Naturally occurring38% described by Estable et al. (1996). Insertions in the
MFNLPs have been described to have positive (Golub variations in a usually conserved Sp1 site were pre-
viously shown to correlate with diminished binding ca-et al., 1990), negative (Koken et al., 1992; Michael et al.,
1994), or no (Estable et al., 1996) effect on transcription. pacity for Sp1 (Michael et al., 1994).
Harrich et al. (1996) have recently shown that someThese insertions are highly variable and their presence
seems not to be associated with a certain clinical status HIV-1 TAR mutants are competent for high levels of gene
expression, but markedly defective in the initiation ofor progression rate. The ACYGCTGA site corresponds to
the 3*-end of the nef open reading frame, which may in reverse transcription. The location of inactivating point
mutations described by Harrich et al. differs from thepart account for the high degree of conservation. Thus,
it remains to be demonstrated if the presence of inser- sequence variations identified in the present study.
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stages of infection display a wide range of sequence polymorphismTherefore, it remains to be elucidated if any promoter/
and transcription activity. J. Virol. 70, 4053–4062.TAR regions analyzed show reduced initiation of reverse
Feng, S., and Holland, E. C. (1988). HIV-1 Tat trans-activation requirestranscription. the loop sequence within TAR. Nature 334, 165–167.
In conclusion, our study shows that the tat1 genes Fisher, A., Feinberg, M., Josephs, S., Harper, M., Marselle, L., Reyes,
and promoter/TAR regions in most nonprogressing and G., Gonda, M., Aldovini, A., Debouk, C., Gallo, R. C., and Wong-Staal,
F. (1986). The transactivator gene of HTLV-III is essential for virusprogressing individuals are intact and show comparable
replication. Nature 320, 367–371.activities in transient reporter assays. However, we can-
Garcia, J. A., Wu, F. K., Mitsuyasu, R., and Gaynor, R. B. (1987). Interac-not exclude the possibility that more substantial differ-
tions of cellular proteins involved in the transcriptional regulation of
ences in promoters would be present in the context of the human immunodeficiency virus. EMBO J. 6, 3761–3770.
replication-competent proviruses in primary cell cultures. Gaynor, R. (1992). Cellular transcription factors involved in the regula-
tion of HIV-1 gene expression. AIDS 6, 347–363.We found some sequence variations in the Sp1 sites,
Golub, E. I., Li, G. G., and Volsky, D. J. (1990). Differences in the basalwhich suggest that more or less active LTR variants may
activity of the long terminal repeat determine different replicativebe present in some individuals. However, more data are
capacities of two closely related human immunodeficiency virus typeneeded to determine if such variants are associated with 1 isolates. J. Virol. 64, 3654–3660.
different rates of disease progression. Greenough, T. C., Somansundaran, M., Brettler, D. B., Hesselton, R. M.,
Alimenti, A., Kirchhoff, F., Panicali, D., and Sullivan, J. L. (1994). Nor-
mal immune function and inability to isolate virus in culture in anACKNOWLEDGMENTS
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